XTX Topco Ltd Acquires 21,814 Shares of Edwards Lifesciences Co. (NYSE:EW)

XTX Topco Ltd increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 69.3% in the third quarter, Holdings Channel.com reports. The firm owned 53,296 shares of the medical research company’s stock after purchasing an additional 21,814 shares during the quarter. XTX Topco Ltd’s holdings in Edwards Lifesciences were worth $3,517,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of EW. First Community Trust NA bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $29,000. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the 3rd quarter worth about $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, HHM Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the second quarter worth about $55,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on EW. Wells Fargo & Company dropped their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Daiwa America downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday. Jefferies Financial Group lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. Finally, Robert W. Baird cut their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $78.35.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $71.53 on Friday. The company has a market capitalization of $42.19 billion, a price-to-earnings ratio of 10.32, a PEG ratio of 4.17 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a 50-day simple moving average of $68.55 and a 200 day simple moving average of $74.76.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.59 earnings per share. On average, sell-side analysts predict that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,000 shares of company stock worth $2,657,000 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.